Prelude Therapeutics vs Pyxis Oncology
PRLD and PYXS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How PRLD and PYXS compare
Prelude Therapeutics is the larger company, worth 2.1 times as much as Pyxis Oncology ($275M against $132M).
Prelude Therapeutics scores higher on the StockData Score (7 against 5 for Pyxis Oncology), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | PRLD | PYXS |
|---|---|---|
| Size and price | ||
| Market cap | $275M | $132M |
| Share price | $3.45 | $1.58 |
| Change, 1 year | 135% | −63.8% |
| Change, 5 years | −76.1% | −87.8% |
| Beta (5Y) | 1.22 | 1.61 |
| Employees | 79 | 56 |
| StockData Score | ||
| Total score | 7 (better) | 5 |
| Valuation score | 1 (better) | 0 |
| Growth score | 1 (better) | 0 |
| Performance score | 0 | 0 |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 12.3× | – |
| P/B | 2.1× (better) | 3.2× |
| FCF yield | −12.1% | – |
| Fair value | $2.06 | – |
| Margin of safety | −67.1% | – |
| Growth | ||
| Revenue growth (TTM) | 220% | – |
| Profitability | ||
| Operating margin | −301% | – |
| Net margin | −270% | – |
| FCF margin | −148% | – |
| Return on equity | −57.7% (better) | −158% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 4.07 (better) | 2.96 |
| Altman Z-score | −2.58 (better) | −10.32 |
| Piotroski F-score | 3 (better) | 1 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 62.2% | 40.9% |
| Held by insiders | 40.5% | 20.4% |
| Insider net buying, 12 months | $25.0M (better) | −$107K |
| Short interest, % of float | 8.8% | 6.8% |
Go deeper
- PRLD stock overview
- PRLD income statement
- PRLD valuation and score
- PYXS stock overview
- PYXS income statement
- PYXS valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.